At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
GSK189075 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Single Ascending Dose Escalation, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 Administered to Subjects With Type 1 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating GSK189075 and placebo for Diabetes Mellitus, Type 1. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin. The clinical effects of the drug in combination with insulin on the body will also be studied. The results will help determine doses of GSK189075 can be studied in the future in the type I diabetes mellitus population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2007
Enrollment StartMar 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedDec 18, 2007
Enrollment StartMar 31, 2008
Primary CompletionDec 18, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.5 years ago
Interventions
GSK189075drug
investigational drug
placebodrug
placebo comparator